 |
|
(... ih-brih-TOO-moh-mab ty-oo-EKS-eh-tan)
| | A radiolabeled monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment of other types of B-cell tumors. It is made up of the monoclonal antibody ibritumomab plus the radioisotope yttrium Y 90. It binds to the protein called CD20, which is found on B cells. The radiation in the yttrium Y 90 may kill the cancer cells. Y 90 ibritumomab tiuxetan is a type of radiopharmaceutical. Also called IDEC-Y2B8, Y 90 Zevalin, and yttrium Y 90 ibritumomab tiuxetan. |
|
|
